Published online Nov 28, 2016. doi: 10.3748/wjg.v22.i44.9674
Peer-review started: August 9, 2016
First decision: August 29, 2016
Revised: September 29, 2016
Accepted: October 30, 2016
Article in press: October 31, 2016
Published online: November 28, 2016
Processing time: 109 Days and 13.7 Hours
Fatty liver, which frequently coexists with necro-inflammatory and fibrotic changes, may occur in the setting of nonalcoholic fatty liver disease (NAFLD) and chronic infections due to either hepatitis C virus (HCV) or human immunodeficiency virus (HIV). These three pathologic conditions are associated with an increased prevalence and incidence of cardiovascular disease (CVD) and type 2 diabetes (T2D). In this multidisciplinary clinical review, we aim to discuss the ever-expanding wealth of clinical and epidemiological evidence supporting a key role of fatty liver in the development of T2D and CVD in patients with NAFLD and in those with HCV or HIV infections. For each of these three common diseases, the epidemiological features, pathophysiologic mechanisms and clinical implications of the presence of fatty liver in predicting the risk of incident T2D and CVD are examined in depth. Collectively, the data discussed in this updated review, which follows an innovative comparative approach, further reinforce the conclusion that the presence of fatty/inflamed/fibrotic liver might be a shared important determinant for the development of T2D and CVD in patients with NAFLD, HCV or HIV. This review may also open new avenues in the clinical and research arenas and paves the way for the planning of future, well-designed prospective and intervention studies.
Core tip: Normally, the liver is almost devoid of fat and fatty changes often coexist with necro-inflammatory and fibrotic changes in the setting of nonalcoholic fatty liver disease (NAFLD), chronic infection due to hepatitis C virus (HCV) or human immunodeficiency virus (HIV), which have all been associated with an increased prevalence and incidence of cardiovascular disease (CVD) and type 2 diabetes (T2D). On these grounds, in this multidisciplinary clinical review, we discuss the ever-expanding wealth of evidence supporting a key role of fatty liver in the development of T2D and CVD both in patients with NAFLD and in those with HCV or HIV infections.